UID:
almafu_9959328214602883
Format:
1 online resource
ISBN:
9783527808694
,
3527808698
,
3527808663
,
9783527808663
,
9783527808687
,
352780868X
,
9783527808670
,
3527808671
Content:
With its focus on drugs so recently introduced that they have yet to be found in any other textbooks or general references, the information and insight found here makes this a genuinely unique handbook and reference. Following the successful approach of the previous volumes in the series, inventors and primary developers of successful drugs from both industry and academia tell the story of the drug's discovery and describe the sometimes twisted route from the first drug candidate molecule to the final marketed drug. The 11 case studies selected describe recent drugs ranging across many therapeutic fields and provide a representative cross-section of present-day drug developments. Backed by plenty of data and chemical information, the insight and experience of today's top drug creators makes this one of the most useful training manuals that a junior medicinal chemist may hope to find. The International Union of Pure and Applied Chemistry has endorsed and sponsored this project because of its high educational merit.
Note:
Includes index.
,
Title from title details screen.
,
General Aspects. New Trends in Drug Discovery / Gerd Schnorrenberg -- Patenting Small and Large Pharmaceutical Molecules / Uwe Albersmeyer, Ralf Malessa, Ulrich Storz -- Drug Class Studies. Kinase Inhibitor Drugs / Peng Wu, Amit Choudhary -- Evolution of Nonsteroidal Androgen Receptor Antagonists / Arwed Cleve, Duy Nguyen -- Case Studies. Development of T-Cell-Engaging Bispecific Antibody Blinatumomab (Blincyto®) for Treatment of B-Cell Malignancies / Patrick A Baeuerle -- Ceritinib: A Potent ALK Inhibitor for the Treatment of Crizotinib-Resistant Non-Small Cell Lung Cancer Tumors / Pierre-Yves Michellys -- Discovery, Development, and Mechanisms of Action of the Human CD38 Antibody Daratumumab / Maarten L Janmaat, Niels WCJ Donk, Jeroen Lammerts Bueren, Tahamtan Ahmadi, A Kate Sasser, Richard K Jansson, Henk M Lokhorst, Paul WHI Parren -- The Discovery of Obeticholic Acid (Ocaliva™): First-in-Class FXR Agonist / Roberto Pellicciari, Mark Pruzanski, Antimo Gioiello -- Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti-CD20 Antibody for the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia / Christian Klein, Ekkehard Mössner, Marina Bacac, Günter Fingerle-Rowson, Pablo Umaña -- Omarigliptin (MARIZEV™, MK-3102) / Tesfaye Biftu -- Opicapone, a Novel Catechol-O-Methyltranferase Inhibitor (COMT) to Manage the Symptoms of Parkinson's Disease / László E Kiss, Maria João Bonifácio, José Francisco Rocha, Patrício Soares- da-Silva -- The Discovery of Osimertinib (TAGRISSO™): An Irreversible Inhibitor of Activating and T790M Resistant Forms of the Epidermal Growth Factor Receptor Tyrosine Kinase for the Treatment of Non-Small Cell Lung Cancer / Michael J Waring -- Discovery of Pitolisant, the First Marketed Histamine H3-Receptor Inverse Agonist/Antagonist for Treating Narcolepsy* / C Robin Ganellin, Jean-Charles Schwartz, Holger Stark -- Discovery and Development of Safinamide, a New Drug for the Treatment of Parkinson's Disease / Paolo Pevarello, Mario Varasi -- Discovery and Development of Trifluridine/Tipiracil (Lonsurf ™) / Norihiko Suzuki, Masanobu Ito, Teiji Takechi.
Language:
English
Keywords:
Electronic books.
;
Electronic books.
;
Electronic books.
DOI:
10.1002/9783527808694
URL:
https://onlinelibrary.wiley.com/doi/book/10.1002/9783527808694
URL:
https://onlinelibrary.wiley.com/doi/book/10.1002/9783527808694
URL:
https://onlinelibrary.wiley.com/doi/book/10.1002/9783527808694
Bookmarklink
